Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : OVX836
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Recipient : Osivax
Deal Size : $10.4 million
Deal Type : Series B Financing
Osivax Gains Strategic Funding for Influenza Vaccine Development
Details : The financing aims to fund the clinical development of OVX836, Osivax’s vaccine candidate. It is being evaluated for the treatment of influenza.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
March 04, 2025
Lead Product(s) : OVX836
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Recipient : Osivax
Deal Size : $10.4 million
Deal Type : Series B Financing
Lead Product(s) : Belumosudil
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Sanofi
Deal Size : Inapplicable
Deal Type : Inapplicable
Meiji Seika Launches REZUROCK® Tablets in Japan for Chronic Graft-Versus-Host Disease
Details : Rezurock (belumosudil mesylate), a selective ROCK2 inhibitor, is indicated for the treatment of patients with Chronic Graft-Versus-Host Disease (chronic GVHD).
Product Name : Rezurock
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 22, 2024
Lead Product(s) : Belumosudil
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Sanofi
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Belumosudil
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Sanofi
Deal Size : Inapplicable
Deal Type : Inapplicable
Meiji Seika Receives Approval for REZUROCK® in Japan for Chronic Graft-Versus-Host Disease
Details : Rezurock (belumosudil mesylate), a selective ROCK2 inhibitor, is indicated for the treatment of patients with Chronic Graft-Versus-Host Disease (chronic GVHD).
Product Name : Rezurock
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 26, 2024
Lead Product(s) : Belumosudil
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Sanofi
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : KD-370
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Zhejiang Hengkang Pharmaceutical
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Through the acquisition, Hengkang entered the field of biosynthesis, improved the commercial production capacity of products in the field of biosynthesis, enriched its product pipeline by adding KD-370, a pentavalent vaccine, approved in Japan.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
October 01, 2023
Lead Product(s) : KD-370
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Zhejiang Hengkang Pharmaceutical
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Belumosudil
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Sanofi
Deal Size : Inapplicable
Deal Type : Inapplicable
New Drug Application for ME3208 Submitted in Japan for Chronic Graft-Versus-Host Disease
Details : Rezurock (belumosudil mesylate), a selective ROCK2 inhibitor, is indicated for the treatment of patients with Chronic Graft-Versus-Host Disease (chronic GVHD).
Product Name : Rezurock
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 27, 2023
Lead Product(s) : Belumosudil
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Sanofi
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cefepime
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
June 15, 2023
Lead Product(s) : Cefepime
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cefepime
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
June 05, 2023
Lead Product(s) : Cefepime
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Belumosudil
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Sanofi
Deal Size : Inapplicable
Deal Type : Inapplicable
ME3208 Receives Orphan Drug Designation in Japan for Chronic Graft-Versus-Host Disease
Details : Rezurock (belumosudil mesylate), a selective ROCK2 inhibitor, is indicated for the treatment of patients with Chronic Graft-Versus-Host Disease (chronic GVHD).
Product Name : Rezurock
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 24, 2023
Lead Product(s) : Belumosudil
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Sanofi
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Foundation for Biomedical Research and Innovation at Kobe
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : A novel anti-PD-1 agonist monoclonal antibody, which inhibits the function of PD-1 (anti-PD-1 blocking antibodies) leading in enhanced anti-tumor immunity.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 16, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Foundation for Biomedical Research and Innovation at Kobe
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ME3183
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In non-clinical studies, ME3183, a selective phosphodiesterase-4 (PDE4) inhibitor, showed greater anti-inflammatory effect and its inhibitory effect on TNF-α production was approximately 30-fold greater than the existing orally-available PDE4 inhibitor ...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 04, 2022
Lead Product(s) : ME3183
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable